美國
證券交易委員會
華盛頓特區20549
S-8表格
註冊聲明
根據.
代表股份的存託憑證
SKYE BIOSCIENCE,
有限公司。
（根據其章程規定的準確名稱） | ||
內華達 | 45-0692882 | |||||||
(所在州或其他司法管轄區) 成立或組織的州） | （IRS僱主 （標識號碼） | |||||||
11250 El Camino Real，套房100，聖地亞哥，加利福尼亞州92130
（總部地址）（郵編）
Skye Bioscience，Inc。
2024年誘因權益激勵計劃
__________________
（計劃的全部標題）
Punit Dhillon
首席執行官
Skye生物科技股份有限公司
El Camino Real地址11250號100室
加利福尼亞州聖地亞哥市92130
(858) 410-0266
________________________________________________________________
（服務代理人的名稱，地址和電話號碼，包括區號）
副本：
Steven G. Rowles 425 Market Street High Bluff Drive 12531號100室 加利福尼亞州聖地亞哥市92130 (858) 720-5100 | Emily k. Beers Morrison & Foerster LLP 2100 L街NW，套房900 華盛頓特區20037 (202) 887-1563 | |||||||
請在以下選項中勾選相應項目以說明該申報人是大型加速報告人、加速報告人、非加速報告人、小型報告公司或新興成長公司。請參閱《交易所法》第120億。2條中「大型加速文件報告人」、「加速報告人」、「小型報告公司」和「新興成長公司」的定義。
大型加速報告人 | ☐ | 加速文件提交人 | ☐ | ||||||||
非加速文件提交人 | ☒ | 較小的報告公司 | ☒ | ||||||||
新興成長公司 | ☐ | ||||||||||
如果是新興成長公司，請勾選選框，如果申報人選擇不使用根據證券法第7(a)(2)(B)條規定提供的任何新的或修訂後的金融會計準則的延長過渡期，請勾選選框。 ☐
第一部分
在10(a) 資料表所需的信息
根據1933年修訂的《證券法》第424條規定及Form S-8見名I條款1和I條款2中指定的信息被省略在這份S-8表格註冊聲明中（「註冊聲明」），以及Form S-8的I部分的引言。包含Form S-8第I部分規定信息的文件將按照《證券法》第428(b)(1)條規定遞交給本註冊聲明涵蓋的權益福利計劃參與者。這些文件以及根據本註冊聲明第II部分第3項目引用的文件合在一起構成符合《證券法》第10(a)條規定的招股說明書。
第II部分
註冊聲明所需的信息
項目3。引用文件
以下文件已提交給證券交易委員會，並通過引用併入本文件：
a. 截至2023年12月31日結束的註冊人年度報告，已向委員會提交 2024年3月22日;
c.註冊人在2024年2月12日提交給委員會的8-k表格的當前報告（而非提供的信息而非提交的信息） 2024年1月29日, February 12, 2024, 3月4日, 2024, 3月1日3, 2024, 2024年6月10日和七月3, 2024；以及幫助孩子們跟蹤他們夏季口腔衛生習慣的材料。
d. 在交易所法案第12（b）條規定的2024年4月10日提交給委員會的申報表8-A中，對註冊人普通股的描述。 表格8-A 爲更新此描述而提交的任何修訂或報告。
在本註冊聲明後，但在提交具有銷售所有擬購股證券或註銷所有擬購股證券文件的後期生效修正案之前根據1934年修訂後的證券交易法案第13（a），13（c），14和15（d）節提交的所有報告和其他文件（包括任何插圖），本表格8-k除外，除非在條款2.02或條款7.01下提交了常規報告，包括任何附帶文件，除非在它們內部另有規定，否則均被認爲被引入本註冊聲明並從提交該文件的日期之日起成爲其一部分。被納入或被認爲被納入本文件的任何聲明，如果本文件或其他稍後提交的文件中也被納入或被認爲被納入，並對該聲明進行了修改或取代，則被認爲已被修改或取代。任何被修改或取代的聲明，除非被修改或取代，否則均不得視爲本註冊聲明的一部分。
項目4。證券描述
不適用。
第5條。專家和律師的利益。
不適用。
第6項。董事和高管的擔保
內華達修訂法典第78.7502條（「NRS」）允許並且公司希望採納，自願爲其董事、官員、僱員和代理人提供如下的豁免賠償。
《內華達州修正法典第78.7502條第(1)款》的子款賦予一家公司賠償任何因爲擔任、曾擔任或受到威脅成爲任何威脅、進行中或已完成的訴訟、起訴或訴訟程序（除了代表公司提起的訴訟）而受到牽連的人，不論是因爲這個人曾經或現任公司的董事、高管、僱員或代理人，或是因爲這個人在公司的要求下擔任
另一家公司、合夥企業、合資企業、信託或其他企業的董事、官員、僱員或代理人；或者作爲有限責任公司的經理，如果此人在訴訟、訴訟或程序中實際合理發生的支出（包括律師費）、判決、罰款和和解金額等方面的行爲，並且（a）未違反其受託責任，而該違反涉及故意不當行爲、欺詐或知法犯法行爲，或者（b）該人以善意行事，並以其合理相信爲公司的最佳利益或不違反的方式行事，並對於任何刑事訴訟或程序，沒有合理理由相信行爲是違法的。
內華達州立法第78.7502節第(2)款賦予公司賠償任何因公司代表獲得判決而面臨威脅、未決或已完成的訴訟的當事人的權力，該判決是因爲該人以上述第(1)款列舉的任何職務行事，包括訴訟及和解過程中實際合理發生的費用和律師費，前提是該人（a）未違反其受託責任，其違反行爲涉及故意不當行爲、欺詐或故意違反法律，或（b）以善意行事，並以合理方式相信行事符合或不違背公司最佳利益，但除非在適當的司法管轄權法院或其他適用的法院經過上訴程序後，裁定該人對公司負有責任，否則不得對該人進行賠償，或支付和解金額給公司，除非申請人依據案情以公正合理的方式有資格獲得法院認定的相應費用賠償。
Subsection (3) of Section 78.7502 of the NRS provides that, unless a court orders indemnification or amounts are advanced pursuant to NRS 78.751(2) or any discretionary indemnification under Subsections (1) or (2) of NRS 75.7502 must be authorized by a determination that such indemnification is proper. This determination must be made by the stockholders, the majority vote of a quorum of the board of the directors not parties to the action, suit or proceeding, or a written opinion by independent legal counsel ordered by a majority of the directors who were not parties to the action, suit, or proceeding, or a quorum of directors who were not parties to the action, suit or proceeding cannot be obtained.
Subsection (1) of Section 78.751 of the NRS provides for mandatory indemnification of any person who is a director, officer, employee or agent to the extent that the person is successful on the merits or otherwise in defense of (i) any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, including, without limitation, an action by or in the right of the corporation, by reason of the fact that the person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise; or (ii) any claim, issue or matter therein, against expenses actually and reasonably incurred by the person in connection with defending the action, including, without limitation, attorney’s fees.
Additionally, NRS 78.138(7) provides, with limited statutory exceptions relating to a director’s duty when confronted with a change or potential change in control of the corporation, or unless the articles of incorporation or an amendment thereto (in each case filed on or after October 1, 2003) provide for greater individual liability, that a director or officer is not individually liable to a corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless it is proven that: (i) the presumption that a director has acted in good faith, on an informed basis and with a view to the interest of the corporation has been overcome; (ii) the act or failure to act constituted a breach of his or her fiduciary duties as a director or officer; and (ii) the breach of those duties involved intentional misconduct, fraud or a knowing violation of law.
Pursuant to the above indemnification provisions, our amended and restated articles of incorporation and amended and restated bylaws provide that we must indemnify and advance expenses to our directors and officers to the fullest extent permitted under the NRS and other applicable law. In addition, we have entered into indemnification agreements with each of our directors and executive officers that require us to indemnify these persons to the full extent provided by the law as stated above.
Item 7. Exemption from Registration Claims.
Not applicable.
Item 8. Exhibits.
Exhibit Number | Description | |||||||
| 3.1 | ||||||||
| 3.2 | ||||||||
| 5.1* | ||||||||
| 23.1* | ||||||||
| 23.2* | ||||||||
| 24.1* | ||||||||
| 99.1 | ||||||||
| 99.2 | ||||||||
| 99.3 | ||||||||
| 107* | ||||||||
_______
* Filed herewith.
Item 9. Undertakings
(a) The undersigned registrant hereby undertakes:
(1) To file, during any period in which offers or sales are being made, a post-
effective amendment to this Registration Statement:
(i) To include any prospectus required by section 10(a)(3) of the Securities
Act of 1933;
(ii) To reflect in the prospectus any facts or events arising after the
effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;
(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section 13 or section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement.
(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(3) To remove from registration by means of a post-effective amendment any of the
securities being registered which remain unsold at the termination of the offering.
(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to section 13(a) or section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of San Diego, state of California, on August 9, 2024.
| SKYE | BIOSCIENCE, INC. | |||||||
| By: | /s/ Kaitlyn Arsenault | |||||||
| Name: | Kaitlyn Arsenault | |||||||
| Title: | Chief Financial Officer | |||||||
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Punit Dhillon and/or Kaitlyn Arsenault as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or any of them, or his/her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:
| Signature | Position | Date | ||||||||||||
| /s/ Punit Dhillon | Chief Executive Officer, Chairman of the Board, and Director | August 9, 2024 | ||||||||||||
| Punit Dhillon | (Principal Executive Officer) | |||||||||||||
| /s/ Kaitlyn Arsenault | Chief Financial Officer | August 9, 2024 | ||||||||||||
| Kaitlyn Arsenault | (Principal Financial Officer and Principal Accounting Officer) | |||||||||||||
| /s/ Deborah Charych | Director | August 9, 2024 | ||||||||||||
| Deborah Charych | ||||||||||||||
| /s/ Annalisa Jenkins | Director | August 9, 2024 | ||||||||||||
Annalisa Jenkins | ||||||||||||||
| /s/ Paul Grayson | Director | August 9, 2024 | ||||||||||||
| Paul Grayson | ||||||||||||||
/s/ Andrew J. Schwab | Director | August 9, 2024 | ||||||||||||
Andrew J. Schwab | ||||||||||||||
| /s/ Karen Smith | Director | August 9, 2024 | ||||||||||||
| Karen Smith | ||||||||||||||